{"entity":{"id":"nct05709249","kind":"trial","name":"Xian-Lian-Jie-Du Optimization Decoction As an Adjuvant Treatment for Prevention of Recurrence of Colon Cancer","aka":[],"tldr":"A phase 3 trial of XLJDOD compound granule in colorectal cancer, run by Jiangsu Famous Medical Technology Co., Ltd., now recruiting.","summary":"Xian-Lian-Jie-Du Optimization Decoction As an Adjuvant Treatment for Prevention of Recurrence of Colon Cancer is a phase 3 interventional study registered as NCT05709249 by Jiangsu Famous Medical Technology Co., Ltd., with 730 participants planned, started 2022-12-01 and due to reach its primary completion in 2027-04-01. Interventions recorded: XLJDOD compound granule and placebo (XLJDOD mimetic agent).","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05709249","url":"https://clinicaltrials.gov/study/NCT05709249"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05709249","phase":"3","setting":"Efficacy of Xian-Lian-Jie-Du Optimization Decoction As an Adjuvant Treatment for Prevention of Recurrence of Stage IIIB/IIIC Colon Cancer：a Study Protocol for a Randomized Controlled Trial","sponsor":"Jiangsu Famous Medical Technology Co., Ltd.","enrolled":730,"outcomes":[]},"route":"/trials/nct05709249/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}]}}